Pipeline
Bonus Biogroup is developing investigational cell therapy and tissue engineering solutions to address conditions involving tissue damage, bone loss, and inflammation. Our proprietary technology platform supports the clinical development of BonoFill and MesenCure, which are currently undergoing evaluation in clinical studies. BonoFill is being investigated as a patient-specific viable bone graft for maxillofacial, dental, and orthopedic applications. MesenCure is being studied as an allogeneic cell therapy for respiratory distress and other inflammatory conditions. Additional research is ongoing to explore new therapeutic indications.

CELL THERAPY
Our cell therapies are designed to leverage the natural properties of mesenchymal cells and provide multi-functional therapeutic mechanisms to modulate inflammation and promote tissue repair. These therapies are currently being evaluated in clinical trials.

TISSUE ENGINEERING
Our tissue-engineered bone graft is designed to address the limitations of existing bone regeneration and reconstruction therapies. It combines autologous mesenchymal cells with a three-dimensional biocompatible and bioactive mineral scaffold and is intended to be tailored to each patient’s unique biological, physical, and clinical needs.
The product candidates mentioned on this website are in the investigational stage and have not been approved by the FDA or any other regulatory authority for commercial use.
Clinical trials are ongoing to evaluate their safety and efficacy.